Visalsok Nou

Investor & Speculator since 2009 | My posts are my personal opinions on the financial and stock markets not financial advice | Please do your own due diligence.

[Visalsok Nou @NouVisalsok]

@BIOTECHSCANNER Welcome back. It has been a while since your last post about IOVA.

[Visalsok Nou @NouVisalsok]

It’s fair to say that anything under $4 looks like a solid buying opportunity for $IOVA.
I think many investors sitting on the sidelines are becoming tempted to buy around $3.85 to $4, while others are still waiting for a deeper pullback toward $3.50. I’m not sure we will see that price range anytime soon.
The next earnings call is less than a month away, and any positive news, stronger guidance, or encouraging update could quickly send the stock much higher.
If you are a investor then you are not late to the game. And if you are a trader, what are you waiting for? What are your thesis to support your decisions?

[Visalsok Nou @NouVisalsok]

@clean_hodl it's getting tighter. we'll see if you're right. i think the next pump is probably gonna be in late August because not much going on in near term; unless Iova surprise us with good news.

[Visalsok Nou @NouVisalsok]

I just want to share a few charts showing what appears to be a repeatable pattern in $IOVA ’s price action.
Right now, the stock continues to swing in both directions within the channel shown on the chart. Any meaningful positive news or company announcement could push the price toward the yellow resistance line. After that, I would expect some type of correction or consolidation (swing traders typically take their profits), which could eventually establish a new trading channel and a higher bottom, as shown on the chart.
I believe the Q2 earnings call, updated guidance, or new clinical trial data could be the catalyst for the next price move.
IOVA management has been relatively quiet lately. My view is that they are focused on execution, and I remain confident in their ability to move the company’s plans forward. The growing number of job openings is also a positive sign. Companies generally do not increase hiring at this level without expecting a larger workload, commercial expansion, or additional operational needs.
For long term IOVA investors, these short term price swings are mostly noise. Veteran investors already understand the thesis and why they own the stock.
New investors should understand that this is a long term, high risk biotechnology investment based on future growth potential. My personal thesis is that IOVA could potentially deliver a least 5x return over the next 2 to 5 years if management executes successfully and the clinical pipeline continues to produce strong results. A future acquisition by a major pharmaceutical company is also very possible, especially if the upcoming data and commercial performance strengthen the company’s position. Many major pharmaceutical companies are currently facing patent cliff when that happens they usually make acquisitions or partnership deals with company like Iovance.
Stay focused on the bigger picture. Staying patient is the key here.

Not financial advice. These are only my personal opinions.

[Visalsok Nou @NouVisalsok]

The Greatest Fireworks Show ever. I got the prime location to watch it, in the middle of the highway right next to the Pentagon. 🇺🇸2️⃣5️⃣0️⃣🎂

[Visalsok Nou @NouVisalsok]

Happy 250th Birthday, America 🇺🇸!

Whether you love it or hate it, you can't deny America's relentless pursuit of greatness. It's a place where you can dream big, chase those dreams, and with hard work and perseverance, achieve them.

Happy Independence Day!

[Visalsok Nou @NouVisalsok]

Look like $ORCL is getting ready to bounce. We shall see in a few months.

[Visalsok Nou @NouVisalsok]

All investing comes with risk, not just stocks. But we can definitely ease our minds and "de-risk" by doing proper research, looking into good business fundamentals, and future growth. Biotech in general, not just IOVA is notoriously high risk. You have to deal with constant delays, crazy price swings, and sometime when you think everything is doing good the stock goes opposite. But if you pick the right company, believe in what they're doing and stay patient ignore the noise then the reward can be massive in a long run. As for now, it seems like regulators are favor in biotech so one less obstacle they have to go through.

[Visalsok Nou @NouVisalsok]

This seems to be a fairly accurate of $IOVA price action for now. Each box represents roughly 7 months of price movement. Once the stock establishes a new trading range, it appears to enter a new tier or phase and then consolidates within that zone before making its next move.
Of course, this pattern can change at any time based on company news, clinical data, regulatory developments, or other significant catalysts. As with any technical setup, the chart provides a framework, not a guarantee.

[Visalsok Nou @NouVisalsok]

This should help $IOVA accelerate the development of its pipeline or future new treatments and potentially bring therapies to market faster, as long as operations remain in good old 'Merica 🇺🇸.

[HHS @HHSGov]

Today, HHS launched a department-wide effort to restore U.S. leadership in clinical trials by reducing unnecessary barriers, accelerating research, expanding patient access to studies, and strengthening America’s biomedical innovation ecosystem.

From FDA and NIH to ARPA-H and ONC, HHS is working to help bring more clinical research, investment, and medical breakthroughs back to the United States.

Read More:

https://t.co/1HPNxBYRWj

[Visalsok Nou @NouVisalsok]

As of now, there isn't any new info that we don't already know. Hopefully, management continues to keep investors updated through earnings calls and conference presentations as additional data becomes available. I think their strategy is to gradually release new information between now and 2027 as they work toward a potential commercial launch in NSCLC. If everything stays on track, mid 2027 remains the target. That said, there are always obstacles and delays in drug development, so expecting progress to extend into late 2027 is probably the more realistic assumption. That's why I looked at the chart and use a more conservative price framework. That way it is more achievable if the company continues executing and the clinical and regulatory timelines remain intact. And not totally tanking if something would go wrong.

[Visalsok Nou @NouVisalsok]

Alright, stay calm, folks. This shouldn't come as a surprise. The market often goes through periods of volatility and correction when a new Fed Chair takes over. Keep your cash ready and be prepared to load up. We'll likely see many more all time highs in the years ahead.

[Visalsok Nou @NouVisalsok]

@Mr_Derivatives Yeah $KEEL with at least 3 contracts announcing soon.

[Visalsok Nou @NouVisalsok]

$KEEL 3 contracts by year end? "MORE".

[Visalsok Nou @NouVisalsok]

$KEEL the cup and handle pattern. Right now, it still on path to form the handle. We'll see in a few months where this thing will go after the handle fully formed.

[Visalsok Nou @NouVisalsok]

@ProfesseurLuigi it needs to get to 6 first then we'll see from there. information from yesterday conference is very assuring for the upside moving forward. but i would want to see a slow consistently price moving upward.

[Visalsok Nou @NouVisalsok]

$IOVA Is $6 coming soon? The chart is starting to support that thesis, but I think it's still a little early to call. I'd like to see a bit more upside and confirmation before I become fully convinced that $6 is the next stop.

[Visalsok Nou @NouVisalsok]

@kainvests @IovanceBio Copy and Paste the whole transcript into ChatGpt and use the Thinking Model not the Instant. Ask it to explain and give the outlook of the company. The response is very hopeful.